VEGFA and chromophobe renal cell carcinoma: Therefore, anti-VEGFA therapy cannot affect neo-angiogenesis or the growth of cRCC but rather through the inhibition of VEGF-dependent interactions between podocytes and glomerular endothelial cells, which disrupt the filtration barrier and lead to proteinuria [29,30].